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Diverse repertoires of hypervariable immunoglobulin receptors (TCR and BCR) recognize antigens
in the adaptive immune system. The development of immunoglobulin receptor repertoire sequencing
methods makes it possible to perform repertoire-wide disease association studies of antigen receptor
sequences. We developed a statistical framework for associating receptors to disease from only a
small cohort of patients, with no need for a control cohort. Our method successfully identifies
previously validated Cytomegalovirus and type 1 diabetes responsive receptors.
T-cell receptors (TCR) and B-cell receptors (BCR) are
hypervariable immunoglobulins that play a key role in
recognizing antigens in the vertebrate immune system.
TCR and BCR are formed in the stochastic process of
V(D)J recombination, creating a diverse sequence reper-
toire. Progress in high throughput sequencing now al-
lows for deep profiling of T-cell repertoires, by establish-
ing a near-complete list of unique receptor sequences, or
“clonotypes,” present in a sample.
Comparison of sequenced repertoires has revealed that
in any pair of individuals, large numbers of TCR se-
quences have the same amino acid sequence [1]. Sev-
eral mechanisms leading to the repertoire overlap have
been identified so far. The first mechanism is convergent
recombination. Due to biases in V(D)J recombination
process, the probability of generation of some receptors
is very high, making them appear in almost every indi-
vidual multiple times and repeatedly sampled in reper-
toire profiling experiments [2]. This sharing does not re-
sult from a common specificity or function of the shared
clonotypes, and may in fact correspond to cells from the
naive compartment in both donors[3], or from function-
ally distinct subsets such as CD4 and CD8 T-cells. The
second possible reason for TCR sequence sharing is spe-
cific to identical twins, who may share T cell clones as a
consequence of cord blood exchange in utero via a shared
placenta [4]. The third and most interesting mechanism
for sharing receptor sequences is convergent selection, in
response to a common antigen. From functional studies,
such as sequencing of MHC-multimer specific T-cells, it
is known that the antigen-specific repertoire is often bi-
ased, and the same antigen-specific TCR sequences can
be found in different individuals [5–7].
Reproducibility of a portion of the antigen-specific T-
cell repertoire in different patients creates an opportu-
nity for disease association studies using T-cell reper-
toire datasets [8, 9]. These studies analyse the TCR se-
quence overlap in large cohorts of healthy controls and
patients to identify shared sequences overrepresented in
the patient cohort. Here we propose a novel computa-
tional method to identify clonotypes which are likely to
be shared because of selection for their response to a
common antigen, instead of convergent recombination.
Our approach is based on a mechanistic model of TCR
recombination and is applicable to small cohorts of pa-
tients, without the need for a healthy control cohort.
As a proof of concept, we applied our method to two
large publicly available TCR beta datasets from Cy-
tomegalovirus (CMV)-positive [9] and type 1 diabetes
(T1D) [10] patients. In both studies the authors found
shared public TCR clonotypes that are specific to CMV-
peptides or self-peptides, respectively. Specificity of these
clonotypes was defined using MHC-multimers. We show
that clonotypes functionally associated with CMV and
T1D in these studies are identified as outliers by our
method.
The main ingredient of our approach is to estimate
the probability of generation of shared clonotypes, and
to use this probability to determine the source of shar-
ing (see Fig. 1). Due to the limited sampling depth of
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FIG. 1. Method principle and pipeline. (Top left) Se-
quence overlap between two TCR or BCR repertoires. (Bot-
tom left) There are two major mechanisms for sequence shar-
ing between two repertoire: convergent recombination and
convergent selection. Because convergent recombination fa-
vors sequences with high generation probability, these two
classes of sequences have different distribution of generative
probability, Pgen(σ). (Right) We estimate the theoretical
Pgen(σ) for each sequence σ and compare it to Pdata(σ), which
is empirically derived from sharing pattern of that sequence
in the cohort. Comparison of these two values allows us to
calculate the analog of a p-value, namely the posterior prob-
ability that the sharing pattern is explained by convergent
recombination alone, with no selection for a common antigen.
any TCR sequencing experiment, chances to sample the
same clonotype twice are low, unless this clonotype is
easy to generate convergently, with many independent
generation events with the same TCR amino acid se-
quence in each individual (convergent recombination),
or if this clonotype underwent clonal expansion, making
its concentration in blood high (convergent selection).
Thus, we reasoned that convergently selected clonotypes
should have a lower generative probability than typical
convergently recombined clonotypes. To test this, we
estimated the generative probability of the TCR’s beta
chain Complementarity Determining Region 3 (CDR3)
amino-acid sequences that were shared between several
patients. Since no algorithm exists that can compute this
generative probability directly, our method relies on the
random generation and translation of massive numbers
of TCR nucleotide sequences using a mechanistic statis-
tical model of V(D)J recombination [11], as can be easily
performed e.g. using the IGoR software [12].
In Fig.2A we plot for each clonotype the number
of donors sharing that clonotype against its generation
probability. Disease-specific TCR variants validated by
functional tests in source studies are circled in red. Note
that validated disease-specific TCRs have a much lower
generation probability than the typical sequences shared
by the same number of donors. We developed a method
of axis transformation (see SI) to compare the model pre-
diction with data values on the same scale (Fig.2B), so
that outliers can be easily identified by their distance to
identity line. Our method can be used to narrow down
the potential candidates for further experimental valida-
tion of responsive receptors.
Our method also identifies other significant outliers
than reported in the source studies (shown in red, and
obtained after multiple-test correction – see Methods),
which may have three possible origins. First, they may
be associated with the condition, but were missed by
the source studies. Second, they may be due to other
factors shared by the patients, such as features involved
in thymic or peripheral selection, or reactivity to other
common conditions than CMV (e.g. influenza infection).
Third, they can be the result of intersample contamina-
tion. Our approach is able to diagnose the last explana-
tion by estimating the likelihood of sharing at the level
of nucleotide sequences (i.e. synonymously), as detailed
in the Methods section.
Our approach can be used on other hypervariable re-
ceptor chains (TCR alpha, BCR heavy and light chains),
as well as other species (mice, fish, etc.). Recent advances
in computational methods allow us to extract TCR reper-
toires from existing RNA-seq data [13, 14]. Huge num-
bers of available RNAseq datasets from patients with var-
ious conditions can be used for analysis and identification
of novel virus, cancer, and self reactive TCR variants us-
ing our method. The more immunoglobulin receptors
with known specificity are found using this type of asso-
ciation mapping, the more clinically relevant information
can be extracted from immunoglobulin repertoire data.
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METHODS
A. Statistical analysis
1. Problem formulation
Our framework is applicable to analyze the outcome
of a next generation sequencing experiment probing the
immune receptor repertoires of n individuals with a given
condition, e.g. CMV or Type 1 diabetes. We denote by
Mi the number of unique amino acid TCR sequences in
patient i, i = 1, . . . , N . For a given TCR amino acid
sequence σ, we set xi = 1 to indicate that σ is present
in patient i’s repertoire, and xi = 0 otherwise. For a
given shared sequence σ, we want to know how likely its
sharing pattern is under the null hypothesis of conver-
gent recombination, correcting for the donors’ different
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FIG. 2. A. CDR3aa of antigen specific clonotypes (red circles) have less generative probability than other
clonotypes shared among the same number of donors. Generation probability for each clonotype in a given VJ
combination, Ppost(σ), plotted against the number of patients with that clonotype. B. Model prediction of generative
probability agrees well with data. To directly compare Ppost(σ) to data, we estimate the empirical probability of occurrence
of sequences, Pdata(σ), from its sharing pattern across donors (see Methods). In A. and B. red dots indicate significant results
(adjusted P < 0.01, Holm’s multiple testing correction), while red circles point to the responsive clonotypes identified in the
source studies.
sampling depths. In other words, is σ overrepresented in
the population of interest? If σ is significantly overrep-
resented, we also want to quantify the size of this effect.
2. Overview
Under the null hypothesis, the presence of σ in a
certain number of donors is explained by independent
convergent V(D)J recombination events in each donor.
Given the total number of recombination events that led
to the sequenced sample of donor i, Ni, the presence of
given amino acid sequence σ in donor is Bernoulli dis-
tributed with probability
pi = 〈xi〉 = (1− Ppost(σ))Ni , (1)
Ppost(σ) = Pgen(σ)×Q, (2)
where Ppost(σ) is the model probability that a recom-
bined product found in a blood sample has sequence σ
under the null hypothesis. It is formed by the prod-
uct of Pgen(σ), the probability to generate the sequence
σ, estimated using a V(D)J recombination model (see
I A 3), and Q, a constant correction factor accounting for
thymic selection (see I A 4). The number of independent
recombination events Ni leading to the observed unique
sequences in a sample i is unknown, because of conver-
gent recombination events within the sample, but it can
be estimated from the number of unique sequences Mi,
using the model distribution Ppost (see I A 6).
We also calculate the posterior distribution of Pdata(σ),
corresponding to the empirical counterpart of Ppost(σ) in
the cohort, inferred from the sharing pattern of σ across
donors. We use information about the presence of σ in
our donors, x1, . . . , xn and the sequencing depth for each
donor, N1, . . . , Nn (see I A 5), yielding the posterior den-
sity: ρ(Pdata|x1, . . . , xN ).
Finally, we estimate the probability, given the obser-
vations, that the true value of Pdata is smaller than the
theoretical value Ppost predicted using V(D)J recombina-
tion model, analogous to a p-value and used to identify
significant effects:
P(Ppost > Pdata) =
∫ Ppost
0
ρ(Pdata|x1, . . . , xn)dPdata.
(3)
To estimate the effect size q(σ) we compare Pdata to
Ppost,
q(σ) =
Pdata(σ)
Ppost(σ)
. (4)
43. Estimation of Pgen, the probability of generation of a
TCR CDR3 amino acid sequence
To procedure outlined above requires to calculate
Pgen(σ), the probability to generate a given CDR3 amino
acid sequence. Methods exist to calculate the probabil-
ity of TCR and BCR nucleotide sequences from a given
recombination model [11, 12], but are impractical to cal-
culate the probability of amino acid sequences, because
of the large number of codon combinations that can lead
to the same amino acid sequence,
∏L
a=1 ncodons(σ(a)),
where L is the sequence length, and ncodons(τ) the num-
ber of codons coding for amino acid τ . The number is
about 1.4 × 107 for a typical CDR3 length of 15 amino
acid.
Instead, we estimated Pgen(σ) using a simple Monte-
Carlo approach. We randomly generated a massive num-
ber (Nsim = 2×109) of recombination scenarios according
to the validated recombination model [11]:
P βrearr(r) = P (V )P (D,J)P (delV |V )P (insV D) (5)
×P (delDl, delDr|D)P (insDJ)P (delJ |J).
The resulting sequences were translated, truncated to
only keep the CDR3, and counted. Pgen(σ) was approx-
imated by the fraction of events thus generated that led
to sequence σ. This approximation becomes more accu-
rate as Nsim increases, with an error on Pgen(σ) scaling
as (Pgen(σ)/Nsim)
1/2.
4. Estimation of the correction factor Q
Not all generated sequences pass selection in the thy-
mus. Pgen systematically underestimates the frequency
of recombination event that eventually make it into the
observed repertoire. To correct for this effect, we esti-
mate a correction factor Q, as was suggested in [15]:
Ppost(σ) = Pgen(σ)×Q. (6)
Contrary to [15], which learned a sequence-specific fac-
tor for each individual, here we assume that all observed
sequences passed thymic selection. Q is a normalization
factor accounting for the fact that just a fraction Q−1
of sequences pass thymic selection. This factor is deter-
mined for each VJ-combination as an offset when plot-
ting logPgen against logP
∗
data (see I A 5 for definition of
P ∗data), using least squares fitting.
5. Estimation of Pdata(σ), the probability of sequence
occurrence in data
The variable xi indicates the presence or absence of
a given TCR amino acid sequence σ in the ith dataset
with Ni recombination events per donor. We want to
estimate Pdata(σ), which is a fraction of recombination
events leading to σ in the population of interest. Ac-
cording to Bayes’ theorem, for a given σ, the probability
density function of Pdata reads:
ρ(Pdata|x1, . . . , xn) = P(x1, . . . , xn|Pdata)ρprior(Pdata)∫ 1
0
P(x1, . . . , xn|Pdata)ρprior(Pdata) dPdata
. (7)
The likelihood is given by a product of Bernouilli probabilities:
P(x1, . . . , xn|Pdata) =
N∏
i=1
[
1− (1− Pdata)Ni
]xi [
(1− Pdata)Ni
]1−xi
, (8)
and a flat prior ρprior(Pdata) = const is used.
We estimate P ∗data (shown in Fig. 2B) as the maximum
of the posterior distribution:
P ∗data = arg max
Pdata
ρ(Pdata|x1, . . . , xn). (9)
6. Estimation of Ni, the number of recombination events
The total number Ni of recombination events in ith
dataset is unknown, but we can count the number of
unique CD3 acid sequences Mi observed in the sequenc-
ing experiment. For a typical TRB experiment, conver-
gent recombination is relatively rare and one could use
Ni ≈ Mi as an approximation. However, for less diverse
loci (e.g TRA), or for much higher sequencing depths, one
should correct for convergent recombination, as the the
5observed number of unique aminoacid sequences could
be much lower than the actual number of corresponding
recombination events.
The average number of unique sequences resulting from
Ni recombination events is, in theory:
〈Mi〉 =
∑
σ∈T
(1− Ppost(σ))Ni . (10)
where T is the set of sequences that can pass thymic se-
lection. To estimate that number, we generate a very
large number Nsim of recombinations, leading to Nuni
unique CDR3 amino acid sequences for which Pgen is es-
timated as explained above. We take T to be a random
subset of unique sequences, T ⊂ {σ1, . . . , σNuni}, of size
|T | = Nuni/Q, and we apply Eq. 10.
Using this equation we plot the calibration curve for
the TRBV5-1 TRBJ2-6 VJ datasets in Fig. 3. For com-
parison the case of no thymic selection (Q = 1) is shown
in red. The inversion of this curve yields Ni as a function
of Mi.
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FIG. 3. Calibration curve for TRBV5-1 TRBJ2-6 com-
bination. Here we plot fraction of unique aminoacid se-
quences to recombination events against logarithm of recom-
bination events number. Blue line corresponds to theoretical
solution with selection, red line corresponds to theoretical so-
lution without selection.
B. Pipeline description
In this section we describe how to apply our algo-
rithm to real data. All the code and data necessary
to reproduce our analysis is available online on github
(https://github.com/pogorely/vdjRec/).
We start with annotated TCR datasets (CDR3 amino
acid sequence, V-segment, J-segment), one per donor.
Such datasets are produced by MiXCR[16], immunoseq
(http://www.adaptivebiotech.com/immunoseq)
and most other software for NGS repertoire
data preprocessing. Data we used was in im-
munoseq format, publicly available from https:
//clients.adaptivebiotech.com/immuneaccess
database.
We proceed as follows:
1. Split datasets by VJ combinations. The resulting
datasets correspond to lists of unique CDR3 amino
acid sequences for each donor and VJ combination.
All following steps should be done independently
for each VJ combination.
2. (Optional). Filter out sequences present in only
one donor to speed up the downstream analysis.
3. Generate a large amount of simulated nucleotide
TCR sequences for a given VJ combination. Ex-
tract and translate their CDR3, and count how
many times each sequence appears in the simulated
set (restricting to sequences actually observed in
donors for better efficiency). The resulting number
divided by the total number of simulated sequences
is an estimate of Pgen.
4. Estimate P ∗data for each sequence in the dataset, see
I A 5.
5. Using P ∗data and Pgen, estimate for each VJ
combination the normalization Q by minimizing∑n
j=1(logP
∗
data(σj) − logPgen(σj) − logQ)2, see
I A 4, where σj , j = 1, . . . , n are the shared se-
quences.
6. Calculate Ppost = Q × Pgen. Calculate the p-value
(Eq. 3) and effect size (Eq. 4).
C. Usage example
1. Data sources
Data from [9] and [10] is publicly available
from the immuneaccess database: https://clients.
adaptivebiotech.com/immuneaccess. For our analy-
sis, we only considered VJ combinations for which the
authors identified condition-associated clonotypes with
MHC-multimer proved specificity. CDR3 aminoacid se-
quences and V and J segment of these TCR clonotypes
are given in Table I.
2. Analysis results
We applied our pipeline to identify CMV-specific and
self-specific TCR sequences listed in Table I. For our anal-
ysis we used only case cohorts, without controls. For
6CDR3aa V-segment J-segment Antigen source Ref.
CASSLAPGATNEKLFF TRBV07-06 TRBJ1-4 CMV [9]
CASSPGQEAGANVLTF TRBV05-01 TRBJ2-6 CMV [9]
CASASANYGYTF TRBV12-3,-4 TRBJ1-2 CMV [9]
CASSLVGGPSSEAFF TRBV05-01 TRBJ1-1 self [10, 17]
TABLE I. Published antigen-specific clonotypes used to test the algorithm.
CDR3aa V J Ag.source Ref. p-value rank p-value Effect size
CASSLAPGATNEKLFF 07-06 1-4 CMV [9] 1/1637 1.2× 10−17 8.8
CASSPGQEAGANVLTF 5-01 2-6 CMV [9] 1/5549 1.8× 10−17 42.3
CASASANYGYTF 12-3,-4 1-2 CMV [9] 40/27669 2.5× 10−14 28.8
CASSLVGGPSSEAFF 5-01 1-1 self [10, 17] 1/2646 9.5× 10−19 524
TABLE II. Output of the algorithm for sequences from table I.
each dataset we followed our pipeline described in I B.
We found that sequences reported in the source studies
as being both significantly enriched in the patient cohort,
and antigen-specific according to MHC-multimers, were
the most significant in 3 out of 4 datasets. In the remain-
ing TRBV12 dataset, the sequence of interest was the top
40 most significant out of 27, 699 sequences present in at
least two CMV-positive donors.
D. Identifying contaminations
Intersample contamination may complicate high-
throughput sequencing data analysis in many ways. It
could occur both during library preparation or the se-
quencing process itself [18]. Contaminations have the
same nucleotide and amino acid sequence in all datasets,
and so our method identifies them as outliers, because
their sharing cannot be explained by a high recombina-
tion probability.
Our method provides a tool to diagnose contamination.
Given an amino-acid sequence present in many donors,
we measure its theoretical nucleotide diversity using the
same simulation approach we used to calculate the gen-
erative probability Pgen of the amino acid sequence (see
I A 3). If the diversity of the simulated nucleotide se-
quences is much larger than observed in the data, it is a
sign of contamination.
We applied this approach to the CDR3 sequence
CASSLVGGPSSEAFF associated to Type 1 diabetes, and
found 19 recombination events consistent with that
amino acid sequence out of our simulated dataset. We
found 18 different nucleotide variants out of the 19 total
possible. In contrast, in the data this clononotype had
the same nucleotide variant in all of the 8 donors in which
it was present. That variant was absent from the simu-
lated set. A one-sided Fisher exact test gives a p < 10−6
probability of this happening by chance, indicating con-
tamination as a likely source of sharing.
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